Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: Impact of clinical status and procedural characteristics

Clinical Research in Cardiology

Volumn 99, Issue 6, 2010, Pages 375-383

  Bauer, Timm ^a   Möllmann, Helge ^a   Weidinger, Franz ^b   Zeymer, Uwe ^c   Seabra Gomes, Ricardo ^d   Eberli, Franz ^e   Serruys, Patrick ^f   Vahanian, Alec ^g   Silber, Sigmund ^h   Wijns, William ⁱ   Hochadel, Matthias ^c   Nef, Holger M ^a   Hamm, Christian W ^a   Marco, Jean ^j   Gitt, Anselm K ^c  

^a KERCKHOFF HEART CENTER   (Germany)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Instituto do Coracao   (Portugal)

^e TRIEMLI HOSPITAL   (Switzerland)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g BICHAT HOSPITAL   (France)

^h Kardiologische Praxis und Praxisklinik   (Germany)

ⁱ CARDIOVASCULAR CENTER   (Belgium)

^j Centre Cardio Thoracique de Monaco   (Monaco)

more..

Author keywords

Clinical practice; Diabetes mellitus; Non ST segment elevation acute coronary syndrome; Percutaneous coronary intervention; Platelet glycoprotein IIb IIIa inhibitor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; EPTIFIBATIDE; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE REGISTRY; DRUG USE; EUROPE; FEMALE; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PROSPECTIVE STUDY; THROMBOSIS; ANTAGONISTS AND INHIBITORS; DIABETIC ANGIOPATHIES; MIDDLE AGED; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; ANGIOPLASTY, BALLOON, CORONARY;

EID: 77954659485     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-010-0130-1     Document Type: Article

References (27)

1. Lefkovits J, Plow EF, Topol EJ (1995) Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332:1553-1559
2. Said SM, Hahn J, Schleyer E, Mü ller M, Fiedler GM, Buerke M, Prondzinsky R (2007) Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment. Clin Res Cardiol 96:61-69
3. Boersma E, Akkerhuls KM, Théroux P, Califf RM, Topol EJ, Simoons ML (1999) Platelet glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 100:2045-2048
4. Iijima R, Ndrepepa G, Mehilli J, Neumann FJ, Schulz S, ten Berg J, Bruskina O, Dotzer F, Dirschinger J, Berger PB, Schömig A, Kastrati A (2008) Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clin Res Cardiol 97:160-168
5. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C, Hamm CW, Robbins MA, Kleimann NS, Théroux P,WhiteHD, Topol EJ (2002) Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J 23:1441-1448
6. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ (1993) Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 21:920-925
7. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A (2000) Impact of diabetes on long-term prognosis in patients with unstable angina and non- Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102:1014-1019
8. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ (2001) Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-STsegment- elevation acute coronary syndromes. Circulation 104:2767-2771
9. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm CW, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W (2005) Guidelines for percutaneous coronary interventions. Eur Heart J 26:804-847 (Pubitemid 40547082)
10. Shechter M, Merz CN, Paul-Labrador MJ, Kaul S (2000) Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 35:300-307
11. Auwerx J, Bouillion R, Collen D, Geboers J (1998) Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 47:68-72
12. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KAA, Hasdai D, Ohman EM, Wallentin L, Wijns W (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598-1660
13. Onuma Y, Kukreja N, Ramcharitar S, Hochadel M, Gitt A, Serruys P (2009) Interventional treatment in diabetics in the era of drug-eluting stents and compliance to the ESC guidelines: lessons learned from the Euro Heart Survey Programme. Euro- Intervention 4:578-587
14. Lenzen MJ, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, Sechtem U, Stahle E, Widimsky P, de Jaegere P, Scholte op Reimer WJ, Mercado N, Wijns W (2005) Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J 26:1169-1179
15. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, Gibson CM, Saucedo JF, Kleinman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM (2004) Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 292:2096-2104
16. Berger PB, Best PJM, Topol EJ, White J, DiBattiste PM, Chan AW, Kristensen SD, Herrmann HC, Moliterno DJ (2005) The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 149:869-875
17. Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ (1997) Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 79:286-291
18. The EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and lowdose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696
19. Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, Cohen DJ, Peterson E, Lakkis N, Herrmann HC, Palabrica TM, Gibson CM (2006) Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECTTIMI- 30 trial. J Am Coll Cardiol 47:2374-2379
20. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA (2003) Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41:718-724
21. Dabbous OH, Anderson FA Jr, Gore JM, Eagle KA, Fox KA, Mehta RH, Goldberg RJ, Agnelli G, Steg PG (2008) Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes. Heart 94:159-165
22. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A (2004) A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350:232-238
23. Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A (2004) Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110:3627-3635
24. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pre-treatment. JAMA 295:1531-1538
25. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FWA, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimising platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 118:1626-1636
26. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward P, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra JW, Mehran R, Ohman EM (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203-2216
27. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, vant Hof A, Berdan LG, Lee KL, Storny JT, Hildermann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK (2009) Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360:2176-2190